|
|
DOYLESTOWN, PA, July 23, 2008 - QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that QuantRx’s FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging.
.
- DOYLESTOWN, PA, May 20, 2008 - QuantRx Biomedical Corporation, (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has entered into an agreement with CytoCore Inc. to supply
.
-
DOYLESTOWN, PA, April 08, 2008 - QuantRx Biomedical Corporation, (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has concluded the development of the Fieldtests ID product
.
DOYLESTOWN, PA, March 27, 2008 - QuantRx Biomedical Corporation, (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that its molecular imaging group, FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, has entered into a license
-
DOYLESTOWN, PA, March 20, 2008 - QuantRx Biomedical Corporation, (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, is commencing Phase I clinical trials for BFPET following institutional review board
.
. |
If you are a stockholder and wish to be added to our electronic mailing list, please email us your name and current email address to receive updates and the latest press releases. |
|
-
DOYLESTOWN, PA, March 12, 2008 - QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that the Canadian Intellectual Property Office (CIPO) has approved its PADKit® patent application.
-
DOYLESTOWN, PA, March 5, 2008 - QuantRx® Biomedical Corporation (OTC BB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry,
today announced that it has entered into a Memorandum of Understanding agreement with Jant Pharmacal to form a strategic alliance to develop and commercialize new technologies and products in the areas of diagnostics and monitoring.
-
DOYLESTOWN, PA, March 3, 2008 - QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, presented positive Phase I safety results for CardioPET, its lead product.
-
DOYLESTOWN, PA, February 21, 2008 - QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that Dr. David Elmaleh, Chairman and Chief Scientific Founder of FluoroPharma, will present findings from the company’s Phase I trial
-
DOYLESTOWN, PA, February 14, 2008 - QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has entered into a second development and manufacturing agreement with ALT BioScience, LLC to continue the development of their professional periodontal screening product
|
|
 |
